Government agencies, health charities and other private partners have launched an international partnership to drive antibacterial research and development over the coming years.
The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a joint effort of the HHS’ Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, the Wellcome Trust of London, the AMR Center of Alderley Park, Boston University School of Law and others. These supporters have pledged several hundred million dollars of funding over the next 5 years to push promising antibiotic candidates through the early stages of development and provide preclinical research expertise to projects chosen by the public-private partnership.
